Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment

Transplantation

Volumn 80, Issue 12, 2005, Pages 1705-1711

  Maluf, Daniel G ^a,c   Mas, Valeria R ^a,b   Archer, Kellie J ^b   Yanek, Kenneth ^a   King, Anne ^a   Ferreira Gonzalez, Andrea ^b   Fisher, Robert A ^a   Posner, Marc ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apolipoprotein E; Hyperlipidemia; Kidney transplantation; Sirolimus

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLESTEROL; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LIPID; LOW DENSITY LIPOPROTEIN; RAPAMYCIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE MARKER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS E; CHOLESTEROL; CREATININE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TRIGLYCERIDES; VIRGINIA;

EID: 30144441514     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000187869.04180.7f     Document Type: Article

References (35)

1. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 Suppl 7: 13.
2. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 2004; 19: 1045.
3. Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003; 16: 118.
4. Marcus AO. Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol Ther 2000; 2: 101.
5. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047.
6. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565.
7. Caforio AL, Tona F, Fortina AB, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962.
8. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170.
9. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute allograft rejection: a randomized multicenter study. The Rapamune US Study Group. Lancet 2000; 356: 194.
10. Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus a potent new immunosuppressive agent for liver transplantation. Transplantation 1999; 67: 505.
11. Stroatman LP, Coles JG. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70: 541.
12. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565.
13. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375.
14. Kahan BD. Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004; 17 Suppl 8: S32.
15. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
16. Vincent S, Planells R, Defoort C, et al. Genetic polymorphisms and lipoprotein response to diets. Proc Nutrition Soc 2002; 61: 427.
17. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and clivage with Whal. J Lipid Res 1990; 31: 545.
18. Rantala M, Rantala TT, Savolainen MJ, et al. Apolipoprotein B gene polymorphisms and serum lipids: meta-analysis of the role of genetic variation in responsiveness to diet. Am J Clin Nutr 2000; 71: 713.
19. Salas J, Jansen S, Lopez-Miranda J, et al. The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats. Am J Clin Nutr 1998; 68: 396.
20. Ostos MA, Lopez-Miranda J, Ordovas JM, et al. Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus. J Lipid Res 1998; 39: 2493.
21. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004; 110: 1868.
22. Song Y, Stampfer MI, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137.
23. Allain G, Poon L, Chan C. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470.
24. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476.
25. Burstein M, Scholnik H, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583.
26. Friedewald W, Levy R, Frederickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499.
27. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036.
28. Morriset JD, Abdel-Fattah G, Kahan B-D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 1435.
29. Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 1272.
30. Corbo RM, Scacchi R, Vilardo T, Ruggeri M. Polymorphisms in the apolipoprotein E gene regulatory region in relation to coronary heart disease and their effect on plasma apolipoprotein E. Clin Chem Lab Med 2001; 39: 2.
31. Bayes B, Pastor MC, Lauzurica R, et al. Apolipoprotein E alleles, dyslipemia and kidney transplantation. Transplant Proc 2002; 34: 373.
32. Balakrishnan S, Colling C, Burkman T, et al. Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. Transplantation 2002; 74: 974.
33. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograff function. Clin Transplant 2004; 18: 288.
34. Hagberg JM, Wilund KR, Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 2000; 4: 101.
35. Nestel P, Simons L, Barter P, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997; 129: 231.